

Nathalie Landry

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8856349/publications.pdf>

Version: 2024-02-01

22
papers

2,022
citations

430874

18
h-index

677142

22
g-index

25
all docs

25
docs citations

25
times ranked

1632
citing authors

#	ARTICLE	IF	CITATIONS
1	Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity. <i>Npj Vaccines</i> , 2022, 7, 42.	6.0	5
2	Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2022, 386, 2084-2096.	27.0	118
3	Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18-49 years of age. <i>Vaccine</i> , 2021, 39, 1528-1533.	3.8	40
4	Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19. <i>Nature Medicine</i> , 2021, 27, 1071-1078.	30.7	206
5	Lack of Effects on Female Fertility or Pre- and Postnatal Development of Offspring in Rats after Exposure to AS03-adjuvanted Recombinant Plant-Derived Virus-Like Particle Vaccine Candidate for COVID-19. <i>Reproductive Toxicology</i> , 2021, 107, 69-80.	2.9	3
6	Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (>65 years): two multicentre, randomised phase 3 trials. <i>Lancet</i> , 2020, 396, 1491-1503.	13.7	132
7	Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages. <i>Npj Vaccines</i> , 2019, 4, 17.	6.0	23
8	Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and >50 years old adults. <i>PLoS ONE</i> , 2019, 14, e0216533.	2.5	92
9	Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial. <i>Npj Vaccines</i> , 2018, 3, 3.	6.0	57
10	The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 647-656.	3.3	46
11	Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy. <i>Vaccine</i> , 2018, 36, 2147-2154.	3.8	37
12	The adjuvant GLA-AF enhances human intradermal vaccine responses. <i>Science Advances</i> , 2018, 4, eaas9930.	10.3	36
13	Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro. <i>Vaccine</i> , 2017, 35, 2592-2599.	3.8	21
14	A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response. <i>Vaccine Journal</i> , 2017, 24, .	3.1	26
15	Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages. <i>Vaccine</i> , 2017, 35, 4629-4636.	3.8	18
16	A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults. <i>Clinical Immunology</i> , 2016, 168, 72-87.	3.2	115
17	Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP). <i>FASEB Journal</i> , 2015, 29, 3817-3827.	0.5	14
18	Influenza virus-like particle vaccines made in <i>Nicotiana benthamiana</i> elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. <i>Clinical Immunology</i> , 2014, 154, 164-177.	3.2	80

#	ARTICLE	IF	CITATIONS
19	Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines. <i>Vaccine</i> , 2014, 32, 6098-6106.	3.8	85
20	The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. <i>Plant Biotechnology Journal</i> , 2010, 8, 607-619.	8.3	319
21	Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza. <i>PLoS ONE</i> , 2010, 5, e15559.	2.5	253
22	Influenza virus-like particles produced by transient expression in <i>Nicotiana benthamiana</i> induce a protective immune response against a lethal viral challenge in mice. <i>Plant Biotechnology Journal</i> , 2008, 6, 930-940.	8.3	251